晚期非小细胞肺癌（NSCLC）中STK11和KEAP1突变检测价值的临床视角数据表1

数据集获取（Figshare）

• 源站标题：Data Sheet 1_Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC.docx
• DOI：10.3389/fonc.2024.1459737.s001
• 发布日期：2024-12-05
• 文件数：1 个
• 文件总体积：807.98 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Clinical_perspectives_on_the_value_of_testing_for_STK11_and_KEAP1_mutations_in_advanced_NSCLC_docx/27965574

命令行下载

curl -L -o "Data Sheet 1_Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC.docx" "https://ndownloader.figshare.com/files/50988921"

文件清单

• Data Sheet 1_Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC.docx（807.98 KB）

文件总体积 807.98 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Standard first-line therapy for patients with metastatic non-small cell lung cancer (mNSCLC) without identified actionable mutations consists of regimens comprising immune checkpoint inhibitors (ICIs), alone or in combination with platinum-based chemotherapy (CTx). However, approximately 20–30% of patients with mNSCLC (including some patients with high tumor programmed cell death ligand-1 expression) display primary resistance to ICIs, either alone or in combination with CTx. Mutations in tumor suppressor genes serine/threonine kinase 11 (STK11), and Kelch-like ECH-associated protein 1 (KEAP1) often detected in patients with Kirsten rat sarcoma virus mutations, are associated with an aggressive disease phenotype and resistance to standard ICI regimens. Consequently, there is an important need for effective treatments for patients with NSCLC with STK11 or KEAP1 mutations. In this article, we describe new data on the prevalence of STK11 and KEAP1 mutations in a large clinical population, consider practicalities around the detection of these mutations using available biomarker testing methodologies, and describe experiences of managing some of these difficult-to-treat patients in our clinical practice.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fonc.2024.1459737.s001（source: https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Clinical_perspectives_on_the_value_of_testing_for_STK11_and_KEAP1_mutations_in_advanced_NSCLC_docx/27965574）。